PROphet
®
PROphet
®
Technology
PROphetNSCLC
TM
Test
Resources
For Patients
For Providers
For Pharma
Science
Publications
Presentations
Clinical studies
Collaborators
About Us
News
In the news
Thought Leadership
Press releases
Meetings & Events
Awards
Contact Us
Careers
US openings
Israel openings
Order a test
PROphet
®
PROphet
®
Technology
PROphetNSCLC
TM
Test
Resources
For Patients
For Providers
For Pharma
Science
Publications
Presentations
Clinical Studies
Collaborators
News
In the News
Thought Leadership
Press Releases
Meetings & Events
Awards
Company
About us
Careers
Contact us
Order a test
In the News
Thought Leadership
Press Releases
Meetings & Events
Awards
September 20, 2021
OncoHost Further Assessing Protein Signature for Predicting NSCLC Patients' Immunotherapy Response
Original source
here.
Recent news
June 18, 2024
OncoHost: Finding New, Better Immunotherapies for Complex Cancers
Read more
June 18, 2024
Immunotherapy Month…and Much More
Read more
June 12, 2024
Companies partner to identify biomarkers for renal cell carcinoma
Read more
June 10, 2024
Dana-Farber Cancer Institute and OncoHost partner for renal cell carcinoma research
Read more
June 4, 2024
OncoHost announces new study on biomarkers for renal cell carcinoma
Read more
June 3, 2024
OncoHost and Dana-Farber Partner on Kidney Cancer (RCC) Biomarker Study
Read more
Read all news